In a January note, RBC Capital Markets assigned Palantir Technologies a price target implying roughly 70% downside, citing an unsustainable valuation near 169 times forward earnings. Analysts pointed out that while Palantir’s revenue has surged—up 63% year-over-year in its most recent quarter—its stock already prices in near-perfect execution and uninterrupted AI spending growth. With a current P/E multiple exceeding 400, RBC warns that any slowdown in enterprise AI budgets or guidance shortfalls could trigger a sharp repricing.

Palantir will report fourth-quarter results on February 2, following the pattern of previous beats that failed to spark sustained rallies. In November, the company “crushed consensus expectations” yet saw its share price retreat from an all-time high; this suggests that simply beating forecasts may no longer suffice. Investors will be watching management’s guidance for AI platform bookings and net revenue retention—historically above 130%—to determine whether Palantir can justify its more than $400 billion market capitalization without resorting to aggressive multiple expansion.

At the World Economic Forum in Davos, CEO Alex Karp argued that Palantir’s AI deployments in healthcare not only accelerate patient intake by 10–15x but also enhance transparency, allowing hospitals to audit decisions on treatment prioritization. He warned that Europe’s low tech adoption represents a “serious and structural problem,” contrasting it with U.S. and Chinese scale deployments. Karp’s remarks underscore Palantir’s positioning as a strategic partner for governments and large enterprises—an angle investors will evaluate as geopolitical and regulatory pressures on AI intensify.